REGISTRATION CLOSE DATE: July 5, 2021, AT 11:59 PM
Join ISPE Canada Affiliate Education Symposium Webinar on July 6, 2021, from 12 noon – 5:00 pm ET, for a webinar focused on the importance of investment in biomanufacturing in Canada. We would like to thank our sponsors, listed below for supporting this event.
Abstract
The continuing pandemic response by the biotech industry has been ground-breaking, requiring collaborative, innovative thinking and partnering for the development of several SARS-CoV-2 vaccines, regulatory approvals, manufacturing, and entire supply chain delivery of desperately needed protection in less than one year. Truly historic!
The Government of Canada introduced the national biomanufacturing strategy to expand the production capacity of critical medicines to prevent and treat diseases such as COVID-19.
This webinar is focused on the importance of biomanufacturing in Canada. The keynote session and the panel discussion addresses why we need to ensure access to critical vaccines, other life-saving therapeutics and prevent locally developed biologics from moving outside of Canada for manufacturing and commercialization, impacting talent and economic growth.
In building biomanufacturing infrastructure, the symposium will examine the challenges companies face due to global competition for resources and how they overcome the challenge of speed and cost of building in the current environment.
The fee includes access to:
- Keynote speaker Mark Lievonen will provide an overview on Canada’s response to COVID-19 including procuring vaccines for Canadians, biomanufacturing challenges and opportunities, pandemic preparedness for the future
- Case study – Construction of the Biomanufacturing Centre (BMC) in Montreal
- Panel of companies currently building biomanufacturing infrastructure in Canada discussing challenges, opportunities and solutions
- Door Prizes
Agenda
| Time | Agenda | Session Description |
|---|---|---|
| 12:00 | Opening of Zoom Meeting | |
| 12:15 | ISPE Canada Affiliate President Welcome
|
ISPE Canada is the leading not-for-profit association supporting pharmaceutical and biotech manufacturing in Canada. ISPE Canada’s President delivers opening remarks and a brief overview of ISPE Canada’s initiatives. |
| 12:30 | Keynote Session: Canada’s COVID-19 Response
J. Mark Lievonen, C.M., Co-Chair, Canada’s COVID-19 Vaccine Task Force |
Procuring vaccines for Canadians, biomanufacturing challenges and opportunities, pandemic preparedness for the future
Thank you to Environmental Systems Corporation, Prosysco Ltd and ACH Engineering Inc. for sponsoring this session |
| 1:30 | Break | |
| 1:45 | Case Study – From Start to Finish in 10 months – A New Vaccine Facility
Isabelle Ahmad, Manager, Facilities & Engineering at BMC André-Pierre Ghys, P.Eng., MBA, President, AP Ghys Expert-Conseil
Jean-Mael Croze, Senior Bio-Process Specialist, Laporte Experts Consiels Inc. |
In June 2020, the Canadian Government decided to build a new facility to produce COVID-19 vaccines for the Canadian population. From July 2020 to May 2021, a new biotech facility was designed and built in Montreal by the NRC. The presentation will discuss the process used to build a 53,000 sq.ft. grass root facility ready for qualification. The presentation will focus on the team spirit, the challenges and the issues encountered during the 10 months. It will be illustrated by real examples of the challenges the team had to face and how it was resolved. |
| 2:45 | Break | |
| 3:00 | Biomanufacturing in Canada, 2017-2021
Frank van Lier, Ph.D., Director R&D Bioprocesss Engineering at National Research Council (NRC) |
End 2016 and beginning 2017, a series of workshops with industry stakeholders and academia took place in Montreal, Toronto, and Vancouver, to discuss Biomanufacturing in Canada. To prepare for these workshops the status of Biologics and Biomanufacturing in Canada was analysed. An update to this analysis will be presented.
The updated analysis takes the conclusions of the workshops into consideration. It shows the updated Canadian pipeline of biologics and will supply additional detail regarding the regional distribution. While the 2017 analysis was mainly focused on mammalian-cell expression of recombinant proteins (monoclonal antibodies), the current presentation will also look into what other types of biologics the Canadian pipeline is made up. We will provide an overview of the current Canadian biomanufacturing sector and its recent developments while taking the different types of biologics into consideration. Furthermore, the increasing need for highly qualified personnel will be explored. The presentation will show that an upward trend of Biologics and the COVID-19 pandemic have created unprecedented demand for Biomanufacturing. Furthermore, as a reaction to weaknesses that the race for COVID-19 vaccine procurement has exposed, several investments – mainly from government sources – have been made in the biomanufacturing sector. It remains to be seen if these efforts will be sufficient to meet the existing and future demand and the challenge of adaptability. |
| 3:30 | Panel Discussion: Challenges and solutions with building biomanufacturing infrastructure in Canada?
Fabien Marino, Vice President, Industrial Affairs & Site Head, Sanofi Pasteur Limited (Toronto) |
The Canadian Government and the private sector biotech companies have made significant investments to strengthen Canada’s biomanufacturing footprint. Roughly $3 billion is committed to building biomanufacturing infrastructure, creating over 2,000 highly skilled new jobs in Canada.
This investment ensures that Canada has sufficient capacity to produce life-saving vaccines and other critical biologic therapies, provides enormous economic benefits associated with growing manufacturing capacity, attracts vaccine developers, and connects Canada’s world-leading life science researchers and start-ups with opportunities to grow and succeed in Canada. Construction of production capacity is in progress from western to eastern Canada. However, along with exciting opportunities for the supply chain in the life-science sector come challenges. This panel discussion, consisting of representatives from biotech companies that are building biomanufacturing capacity, will address the challenges, opportunities, and innovative solutions they have implemented. Thank you to Net Squares, CRB and CHEME ENGINEERING INC. for sponsoring this session |
| 5:00 | Closing Remarks and Door Prizes
|
|
Location
Zoom. A meeting invite with the link will be sent to all registrants prior to the event. Please ensure you have the app downloaded prior to the event.
Speakers
Attendee Registration
| Registration Category | Fee |
|---|---|
| Members | $30.00 |
| Non-members | $50.00 |
Sponsors Registration
| Item | Fee | Features |
|---|---|---|
| Keynote Session | $450 | - Clickable logo on Event home page - Company mention at beginning of Keynote Session - Logo included on event poster in ISPE social media platforms |
| Panel Session | $600 | - Clickable logo on event home page - Company mention at beginning of Panel Discussion - Logo included on event poster in ISPE social media platforms |
| Website Logo | $300 | - Clickable logo on Event home page |
| Door Prizes | $100 | - Mention during Prize draw |
SPONSORS
ISPE Canada Affiliate sincerely thanks the ongoing support of our sponsors and exhibitors. This support helps to make our events possible at a reasonable cost to the attendees.
